Eric S Rosenberg

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection
    Eric S Rosenberg
    Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 5:e10555. 2010
  2. ncbi Limited durability of viral control following treated acute HIV infection
    Daniel E Kaufmann
    Partners AIDS Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    PLoS Med 1:e36. 2004
  3. ncbi Longitudinal analysis of clinical markers following antiretroviral therapy initiated during acute or early HIV type 1 infection
    Sigall Kassutto
    Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Clin Infect Dis 42:1024-31. 2006
  4. ncbi Fully differentiated HIV-1 specific CD8+ T effector cells are more frequently detectable in controlled than in progressive HIV-1 infection
    Marylyn M Addo
    Partners AIDS Research Center and Infectious Disease Division, Massachusetts General Hospital and Harvard Medical School Division of AIDS, Boston, Massachusetts, United States of America
    PLoS ONE 2:e321. 2007
  5. ncbi Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection
    Marcus Altfeld
    Partners AIDS Research Center and Infectious Disease Division, Massachusetts General Hospital, Boston, Massachusetts, USA
    AIDS 17:2581-91. 2003
  6. ncbi Enhanced detection of human immunodeficiency virus type 1-specific T-cell responses to highly variable regions by using peptides based on autologous virus sequences
    Marcus Altfeld
    Partners AIDS Research Center and Infectious Disease Unit, Massachusetts General Hospital, and Division of AIDS, Harvard Medical School, Boston, Massachusetts, USA
    J Virol 77:7330-40. 2003
  7. ncbi Consistent patterns in the development and immunodominance of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T-cell responses following acute HIV-1 infection
    Xu G Yu
    Partners AIDS Research Center and Infectious Disease Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Virol 76:8690-701. 2002
  8. ncbi Differential regulation of toll-like receptor pathways in acute and chronic HIV-1 infection
    J Judy Chang
    Ragon Institute of Massachusetts General Hospital, Massachusetts Institute Technology and Harvard, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA
    AIDS 26:533-41. 2012
  9. ncbi Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells
    Hendrik Streeck
    Ragon Institute of MGH, MIT, and Harvard, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02129, USA
    J Virol 83:7641-8. 2009
  10. ncbi Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cells
    Hendrik Streeck
    Partners AIDS Research Center, Infectious Disease Unit, Massachusetts General Hospital and Division of AIDS, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS Med 5:e100. 2008

Collaborators

Detail Information

Publications20

  1. ncbi Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection
    Eric S Rosenberg
    Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 5:e10555. 2010
    ..clinicaltrials.gov NCT00125099)..
  2. ncbi Limited durability of viral control following treated acute HIV infection
    Daniel E Kaufmann
    Partners AIDS Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    PLoS Med 1:e36. 2004
    ..These data may be relevant to current efforts to develop an HIV-1 vaccine designed to retard disease progression rather than prevent infection since they indicate that durable maintenance of low-level viremia may be difficult to achieve...
  3. ncbi Longitudinal analysis of clinical markers following antiretroviral therapy initiated during acute or early HIV type 1 infection
    Sigall Kassutto
    Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Clin Infect Dis 42:1024-31. 2006
    ..Protease inhibitor-based and nonnucleoside reverse-transcriptase inhibitor-based regimens show comparable performance in tolerability, time to virological suppression, and CD4+ cell count when used as a first regimen...
  4. ncbi Fully differentiated HIV-1 specific CD8+ T effector cells are more frequently detectable in controlled than in progressive HIV-1 infection
    Marylyn M Addo
    Partners AIDS Research Center and Infectious Disease Division, Massachusetts General Hospital and Harvard Medical School Division of AIDS, Boston, Massachusetts, United States of America
    PLoS ONE 2:e321. 2007
    ..Recent data suggest that impaired maturation, as defined by the lineage markers CD45RA and CCR7, may contribute to a lack of immune control by these responses...
  5. ncbi Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection
    Marcus Altfeld
    Partners AIDS Research Center and Infectious Disease Division, Massachusetts General Hospital, Boston, Massachusetts, USA
    AIDS 17:2581-91. 2003
    ..CONCLUSION: These data demonstrate that host genetic factors can influence the clinical manifestations of acute HIV-1 infection and provide a functional link between HLA-B57 and viral immune control...
  6. ncbi Enhanced detection of human immunodeficiency virus type 1-specific T-cell responses to highly variable regions by using peptides based on autologous virus sequences
    Marcus Altfeld
    Partners AIDS Research Center and Infectious Disease Unit, Massachusetts General Hospital, and Division of AIDS, Harvard Medical School, Boston, Massachusetts, USA
    J Virol 77:7330-40. 2003
    ..They also demonstrate that CD8 T-cell responses to the variable HIV-1 proteins are more common than previously reported...
  7. ncbi Consistent patterns in the development and immunodominance of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T-cell responses following acute HIV-1 infection
    Xu G Yu
    Partners AIDS Research Center and Infectious Disease Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Virol 76:8690-701. 2002
    ..These studies have important implications for vaccine design and evaluation...
  8. ncbi Differential regulation of toll-like receptor pathways in acute and chronic HIV-1 infection
    J Judy Chang
    Ragon Institute of Massachusetts General Hospital, Massachusetts Institute Technology and Harvard, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA
    AIDS 26:533-41. 2012
    ..Studies assessing the consequences of HIV-1 infection on the ability of innate immune cells to respond to TLR stimulation have come to varying conclusions...
  9. ncbi Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells
    Hendrik Streeck
    Ragon Institute of MGH, MIT, and Harvard, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02129, USA
    J Virol 83:7641-8. 2009
    ..Taken together, these data show that the specificity of the initial CTL response to HIV is critical for the subsequent control of viremia and have important implications for the rational selection of antigens for future HIV-1 vaccines...
  10. ncbi Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cells
    Hendrik Streeck
    Partners AIDS Research Center, Infectious Disease Unit, Massachusetts General Hospital and Division of AIDS, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS Med 5:e100. 2008
    ....
  11. ncbi Incomplete HIV type 1 antibody evolution and seroreversion in acutely infected individuals treated with early antiretroviral therapy
    Sigall Kassutto
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Clin Infect Dis 40:868-73. 2005
    ....
  12. ncbi Shelterin dysfunction and p16(INK4a)-mediated growth inhibition in HIV-1-specific CD8 T cells
    Mathias Lichterfeld
    Infectious Disease Division, Massachusetts General Hospital, Boston, Massachusetts, USA
    J Virol 86:5533-40. 2012
    ..These data suggest that shelterin dysfunction and ensuing upregulation of the tumor suppressor p16(INK4a) promote accelerated aging of HIV-1-specific T cells during progressive HIV-1 infection...
  13. ncbi Human immunodeficiency virus type 1-hepatitis C virus coinfection: intraindividual comparison of cellular immune responses against two persistent viruses
    Georg M Lauer
    Partners AIDS Research Center, Infectious Disease Division, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    J Virol 76:2817-26. 2002
    ..In addition, they show a consistent and profound impairment in cellular immune responses to HCV compared to HIV-1 in HIV-1-HCV-coinfected persons...
  14. ncbi Functional characterization of HLA-G⁺ regulatory T cells in HIV-1 infection
    Chun Li
    Ragon Institute of MGH, MIT and Harvard University, Boston, Massachusetts, United States of America
    PLoS Pathog 9:e1003140. 2013
    ....
  15. ncbi HLA class I subtype-dependent expansion of KIR3DS1+ and KIR3DL1+ NK cells during acute human immunodeficiency virus type 1 infection
    Galit Alter
    Ragon Institute of MGH, MIT, Boston, Massachusetts, USA
    J Virol 83:6798-805. 2009
    ..These data demonstrate for the first time the HLA class I subtype-dependent expansion of specific KIR(+) NK cells during an acute viral infection in humans...
  16. ncbi Transcriptional profiling of CD4 T cells identifies distinct subgroups of HIV-1 elite controllers
    Francois Vigneault
    Department of Genetics, Harvard Medical School, Boston, Massachusetts, USA
    J Virol 85:3015-9. 2011
    ..Thus, these data identify a specific subgroup of elite controllers whose immunological and gene expression characteristics approximate those of HIV-1-negative persons...
  17. ncbi CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21
    Huabiao Chen
    Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Boston, Massachusetts, USA
    J Clin Invest 121:1549-60. 2011
    ..These data demonstrate a mechanism of host resistance to HIV-1 in elite controllers and may open novel perspectives for clinical strategies to prevent or treat HIV-1 infection...
  18. ncbi Primary HIV type 1 infection
    Sigall Kassutto
    Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Clin Infect Dis 38:1447-53. 2004
    ..We review the basic principles of primary HIV-1 infection, clinical and diagnostic markers of acute seroconversion, approaches to management, and new therapeutic strategies...
  19. ncbi Using mathematical modeling and control to develop structured treatment interruption strategies for HIV infection
    Eric S Rosenberg
    Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Drug Alcohol Depend 88:S41-51. 2007
    ..We advocate that, when such mathematical representations of processes underlying a disease or disorder are available, they can be an important tool for suggesting adaptive treatment strategies for clinical study...
  20. ncbi Important contribution of p15 Gag-specific responses to the total Gag-specific CTL responses
    Xu G Yu
    Partners AIDS Research Center, Infectious Disease Division, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
    AIDS 16:321-8. 2002
    ....